[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100649087","oral-gnrh-antagonist-linzagolix-versus-injectable-gnrh-antagonist-and-progestin-primed-ovarian-stimulation-ppos-in-controlled-ovarian-stimulation-for-in-vitro-fertilization-a-prospective-comparative-observational-study-100649087",false,"NCT07732348","Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist and Progestin-primed Ovarian Stimulation (PPOS) in Controlled Ovarian Stimulation for in Vitro Fertilization: a Prospective Comparative Observational Study","Inclusion Criteria:\n\n* Female, aged 18 to 42 years\n* Indication for IVF\u002FICSI with controlled ovarian stimulation at CENTRO AMBRA\n* Population unselected for ovarian reserve (normal, poor, and high responders are eligible)\n* Written informed consent, including consent for off-label use of linzagolix and for data processing\n* For the two antagonist arms (Linzagolix and Injectable GnRH Antagonist): acceptance of randomization\n\nExclusion Criteria:\n\n* Known contraindications or hypersensitivity to the study drugs\n* Uterine pathology relevant to the study outcome (e.g., uterine malformations, significant submucosal fibroids)\n* Contraindications to pregnancy or to ovarian stimulation\n* Concurrent participation in another interfering interventional study","FEMALE","18 Years","42 Years",{"count":19,"type":20},195,"ESTIMATED","OBSERVATIONAL","Preventing a premature rise in luteinizing hormone (LH) is essential during ovarian stimulation for in vitro fertilization (IVF), because such a rise can reduce the number of eggs collected. Current practice relies on either a daily injectable GnRH antagonist or an oral progestin (PPOS), which requires that all embryos be frozen.\n\nLinzagolix is an oral GnRH antagonist already approved for uterine fibroids and endometriosis. It has not previously been used to control ovarian stimulation for IVF; this study represents its first use for this purpose.\n\nThis is an observational study: participants are not randomly assigned to a treatment. Each woman receives one of three approaches - oral linzagolix, an injectable GnRH antagonist (ganirelix or cetrorelix), or PPOS - chosen by the clinical team based on her individual situation. The three groups are then compared using statistical adjustment for baseline differences between them.\n\nThe study will enroll approximately 195 women undergoing IVF or ICSI, aged 18 to \\[42\\], who are not selected based on ovarian reserve. All participants receive individualized gonadotropin stimulation and standard monitoring; only the method used to prevent premature ovulation differs by group.\n\nThe main question is whether linzagolix leads to a similar number of mature eggs (MII) retrieved compared with the injectable antagonist. The study will also assess how well each approach suppresses LH, safety (including ovarian hyperstimulation), and the number of injections needed.",[24,25],"Infertility, Female","Ovulation Induction",[27,28,29,30,31,32,33,34],"Oral GnRH Antagonist","Linzagolix","Controlled Ovarian Stimulation","In Vitro Fertilization","ICSI","Progestin-Primed Ovarian Stimulation","Oocyte Maturation","OHSS Prevention","NOT_YET_RECRUITING","2026-07-31",{"date":38,"type":39},"2026-08-03","ACTUAL",{"date":41,"type":20},"2026-09",{"date":43,"type":20},"2026-12",{"name":45,"class":46},"Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":55,"targetDuration":57,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100649430","hysteroscopy-and-cd138-plasma-cell-density-in-chronic-endometritis-100649430","NCT07733713","Hysteroscopy and CD138+ Plasma Cell Density in Chronic Endometritis","Correlation Between Hysteroscopic Signs of Chronic Endometritis and CD138-Positive Endometrial Plasma Cell Density in Women Undergoing Outpatient Hysteroscopy: a Prospective, Single-Centre Observational Study","Inclusion Criteria:\n\n* Woman aged 18-46 years undergoing office hysteroscopy with endometrial biopsy as part of her clinical work-up (including assisted reproduction\u002FPMA pathways), for any indication (recurrent implantation failure, recurrent pregnancy loss, or other).\n* Examination performed during the early-to-mid proliferative phase (cycle days 6-12) of a spontaneous cycle not exposed to exogenous progestins\n* Written informed consent to participation and to data processing\n\nExclusion Criteria:\n\n* Current or suspected pregnancy\n* Postmenopausal status\n* Clinically active pelvic or lower genital tract infection\n* Systemic antibiotic use within the preceding 4 weeks\n* Use of exogenous progestins or other hormonal therapy within the preceding 4 weeks\n* Submucous myoma, endometrial polyp, or synechiae precluding reliable\n* assessment of the endometrial surface\n* Inability to obtain adequate endometrial tissue for immunohistochemistry","46 Years",{"count":56,"type":20},100,"1 Year","The goal of this observational study is to learn if a hysteroscopy exam alone can find chronic endometritis, a long-lasting inflammation of the lining of the uterus. A hysteroscopy is an exam that looks inside the uterus with a thin camera. Chronic endometritis is usually confirmed with a lab test that counts CD138-positive cells, a type of immune cell, in a small tissue sample from the uterus.\n\nAbout 100 women will take part. All are already having a hysteroscopy and a tissue sample as part of their fertility care, often after repeated failed embryo transfers or repeated miscarriage.\n\nThe main question it aims to answer is:\n\nDo the visual signs seen during hysteroscopy relate closely enough to the CD138 cell count to reliably find chronic endometritis without a lab test?\n\nParticipants will:\n\nHave a hysteroscopy exam and a tissue sample from the uterus, both already part of their routine fertility care Have their hysteroscopy video reviewed by two doctors who do not know the tissue sample results Have their tissue sample checked in the lab for CD138 cells",[60],"Chronic Endometritis",[62,63,64,65,66,67,68],"CD138","Endometrial Plasma Cells","Syndecan-1","Hysteroscopy","Diagnostic Accuracy","Recurrent Implantation Failure","Recurrent Pregnancy Loss","2026-07-24",{"date":71,"type":39},"2026-07-29",{"date":73,"type":20},"2026-09-14",{"date":75,"type":20},"2026-11-26",{"name":45,"class":46},""]